Does free to total ratio of prostate-specific antigen alter decision- making on prostatic biopsy?

Urology

Volumn 48, Issue 6 SUPPL., 1996, Pages 71-75

  Alivizatos, Gerasimos ^a,b   Deliveliotis, Charalambos ^a   Mitropoulos, Dionysios ^a   Raptides, Greg ^a   Louras, George ^a   Karayiannis, Aris ^a   Becopoulos, Theodosis ^a   Dimopoulos, Athanasios Meletios ^a  

^a SISMANOGLIO HOSPITAL   (Greece)

^b NONE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD LEVEL; DIAGNOSTIC VALUE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CARCINOMA; PROSTATE DISEASE;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 0030449001     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(96)00614-0     Document Type: Article

References (20)

1. Dillioglugil O, Miles BJ, and Scardino PT: Current controversies in the management of localized prostate cancer. Eur Urol 28: 85-101, 1995.
2. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, de Kernion JB, Ratlift TL, Kavoussi LR, Dalkin BL, Waters WW, MacFarlane MT, and Southwick PC: Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6630 men. J Urol 151: 1283-1290, 1994.
3. Babaian RJ, Fritsche HA, and Evans RB: Prostate specific antigen. J Clin Lab Anal 4: 134-137, 1990.
4. Brawer MK, Chetner MP, Beatie J, Buchner DM, Vessella RL, and Lange PH: Screening for prostatic carcinoma with prostate specific antigen. J Urol 147: 846-851,1992.
5. Catalona WJ, Smith DS, Ratliff TI, Dodds KM, Coplen DE, Yuan JJJ, Petros JA, and Andriole GL: Measurment of prostate specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324: 1156-1161,1991.
6. Benson MC, Whang IS, Olsson CA, McMahon DJ, and Cooner WH: The use of prostatic specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol 147: 817-821, 1992.
7. Carter HB, Pearson JD, Metter EJ, Brant LJ, Chan DW, Andres R, Fozard JL, and Walsh PC: Longitudinal evaluation of prostate specific antigen levels in men with and without prostate disease. JAMA 267: 2215-2221, 1992.
8. Van Iersel MP, Witjes WPJ, De La Rosette JJMCH, and Oosterhof GON: Prostate-specific antigen density: correlation with histological diagnosis of prostate cancer, benign prostatic hyperplasia and prostatitis. Br J Urol 76: 47-53, 1995.
9. Cookson MS, Floyd MK, Ball TP, Miller EK, and Sarosdy MF: The lack of predictive value of prostate specific antigen density in the detection of prostate cancer in patients with normal rectal examinations and intermediate prostate specific antigen levels. J Urol 154: 1070-1073, 1995.
10. Riehmann M, Rhodes PR, Cook TD, Grose GS, and Bruskewitz RC: Analysis of variations in prostate specific antigen values. Urology 42: 390-397, 1993.
11. Oesterling JE, Jacobsen SJ, and Lieber MM: Serum prostate specific antigen in a community based population of healthy men. Establishment of age specific reference ranges. JAMA 270: 860-865,1993.
12. Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tchkanen K, and Alfthan O: A complex between prostate specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 51: 222-226, 1991.
13. Lilja H, Christensson A, Dablen U, Matikainen MT, Nilsson O, Pettersson K, and Lorgen T: Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem 37: 1618-1625, 1991.
14. Christensson A, Bjork T, Nilsson O, Dahlen U, Matikainen M, Cockett ATK, Abrahamsson PA, and Lilja H: Serum prostate specific antigen complexed to al antichymotrypsin as an indicator of prostate cancer. J Urol 150:100-105, 1993.
15. Oesterling JE, Jacobsen SJ, Klee GG, Peterson K, Piironen T, Abrahmsson PA, Stenman UH, Dowell B, Lorgren T, and Lilja H: Free complexed and total serum prostate specific antigen. The establishment of appropriate reference ranges for their concentrations and ratios. J Urol 154: 1090-1095,1995.
16. Deliveliotis CH, Alivizatos G, Karayiannis A, Kontothanasis D, Makrychoritis K, Lysiotis P, and Dimopoulos MA: The value of prostatic specific antigen in the early diagnosis of prostatic cancer: a Greek view. Br J Urol 75: 637-641, 1995.
17. Hanley JA, McNeil BJ: The meaning and use of the area under a receiver operating characteristic (ROC) curve. Diagn Radiol 143: 29-36, 1982.
18. Luderer A, Chen Y, Soriano T, Kramp W, Carlson G, Cuny C, Sharp T, Smith W, Petteway J, Brawer M, and Thiel R: Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. Urology 46: 187-194, 1995.
19. Bangma C, Kranse R, Blijenberg B, and Schroder F: The value of screening tests in the detection of prostate cancer. Part II. Retrospective analysis of free/total prostate-specific analysis ratio, age-specific reference ranges, and PSA density. Urology 46: 779-784, 1995.
20. Colberg JW, Smith DS, and Catalona WJ: Prevalence and pathological extent of prostate cancer in men with prostate specific antigen levels of 2.9 to 4.0 ng/ml. J Urol 147: 507-509, 1993.